During the corresponding time, Elutia Inc saw a revenue deteriorated by -59.94 % year on year, sequentially revenue fell by -13.38 %. While revenue at the Elutia Inc 's corporate clients
Elutia Inc's Comment on Sales, Marketing and Customers
The company operates in the cardiovascular repair and soft tissue repair markets, offering products including ProxiCor, Tyke, VasCure, and SimpliDerm. Its products compete with other cardiovascular repair and human-derived acellular dermis products, such as bovine pericardium and synthetic patch materials. Competitors include Gore's Gore-tex, Terumo's Vascutek, AbbVie's AlloDerm and Strattice, MTF's FlexHD, Stryker's DermACELL, Evergen's Cortiva, and Integra's SurgiMend. The company also faces competition in recruiting qualified personnel and acquiring complementary technologies. Reimbursement coverage for SimpliDerm varies, with some national and regional third-party payors providing specific reimbursement, though most do not. The company anticipates intense competition and highlights the importance of proprietary, timely, cost-effective, safe, and effective products supported by adequate payor coverage and a strong sales strategy. Customers and markets referenced include AbbVie, Evergen, Gore, Integra, MTF, Stryker, and Terumo.
Groundbreaking Study Confirms the Efficacy of Elutia s Antibiotic-Eluting BioEnvelope, EluPro, in Preventing Cardiac Device Infections Elutia Inc. a leader in the development of advanced medical devices, has recently unveiled a crucial publication that underscores the formidable effectiveness of its flagship product, the EluPro Antibiotic-Eluting BioEnvelope. This peer-reviewed study, epitomizing rigorous scientific scrutiny, provides robust evidence attesting to EluPro’s capacity to eradicate bacteria commonly associated with infections following the implantation of cardiac devices.The publication presents data derived from an established preclinical infection model, emphasizing the clinical significance ...
Elutia Inc’s Comment on Sales, Marketing and Customers
The company operates in the cardiovascular repair and soft tissue repair markets, offering products including ProxiCor, Tyke, VasCure, and SimpliDerm. Its products compete with other cardiovascular repair and human-derived acellular dermis products, such as bovine pericardium and synthetic patch materials. Competitors include Gore's Gore-tex, Terumo's Vascutek, AbbVie's AlloDerm and Strattice, MTF's FlexHD, Stryker's DermACELL, Evergen's Cortiva, and Integra's SurgiMend. The company also faces competition in recruiting qualified personnel and acquiring complementary technologies. Reimbursement coverage for SimpliDerm varies, with some national and regional third-party payors providing specific reimbursement, though most do not. The company anticipates intense competition and highlights the importance of proprietary, timely, cost-effective, safe, and effective products supported by adequate payor coverage and a strong sales strategy. Customers and markets referenced include AbbVie, Evergen, Gore, Integra, MTF, Stryker, and Terumo.
Sources:
Elutia Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Elutia Inc’s corporate clients.
For your research, we’ve provided 9 tables on Elutia Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
89.37 %